Next Article in Journal
EMT and Treatment Resistance in Pancreatic Cancer
Next Article in Special Issue
From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
Previous Article in Journal
The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
Previous Article in Special Issue
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(9), 123;

Anaplastic Lymphoma Kinase in Cutaneous Malignancies

Harvard Medical School, Boston, MA 02115, USA
Department of Dermatology, Brigham and Women’s Hospital, Boston, MA 02115, USA
Author to whom correspondence should be addressed.
Academic Editor: Raymond Lai
Received: 8 August 2017 / Revised: 5 September 2017 / Accepted: 10 September 2017 / Published: 12 September 2017
(This article belongs to the Special Issue Targeting ALK in Cancer)
Full-Text   |   PDF [243 KB, uploaded 12 September 2017]


Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies. ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma. The characterization of ALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases. View Full-Text
Keywords: anaplastic lymphoma kinase; cutaneous malignancy; anaplastic large cell lymphoma; crizotinib anaplastic lymphoma kinase; cutaneous malignancy; anaplastic large cell lymphoma; crizotinib
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Cao, S.; Nambudiri, V.E. Anaplastic Lymphoma Kinase in Cutaneous Malignancies. Cancers 2017, 9, 123.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top